German Chancellor Angela Merkel Starts the New PacBio RS at the Max Delbrück Center of Molecular Medicine

BERLIN–(BUSINESS WIRE)–

During a visit today to the Max Delbrück Center of Molecular Medicine in

Berlin-Buch (MDC), German Chancellor Angela Merkel started up the newly

installed PacBio RS, the single molecule, real-time (SMRT™) DNA

sequencing system from Pacific Biosciences of California, Inc. (NASDAQ:

PACB). PacBio Scientific Fellow Dr. Jonas Korlach, co-inventor of the

technology and a native Berliner, was also present at the ceremony.

Professor Nikolaus Rajewsky of the MDC commented: “The outstanding

characteristics of SMRT technology are that not only can one watch how

DNA is being synthesized, but also that the data it generates will

enable us to quantitatively analyze gene regulation, RNA function,

epigenetic gene regulation, DNA modification and genome structure. This

technology allows us deeper insight into gene regulatory networks and

opens new approaches to personalized medicine.”

The new PacBio RS sequencing system at MDC marks the third

installation of the system in Europe. Terry Pizzie, Vice President of

Europe for Pacific Biosciences, said: “We have received tremendous

interest from the European market since we began commercial sales in

April. It is wonderful to see the product receive this level of

recognition from both our customers at MDC and the Chancellor, who is

also a physicist herself by training.”

For Dr. Korlach, the event was also symbolic. “I was here when the

Berlin Wall came down, which opened the possibilities for me to study

abroad and led to co-inventing this technology with Steve Turner at

Cornell University,” he said. “It’s an honor to be back where I started

and sharing the product of our years of hard work where it will now help

contribute to the advancement of scientific discovery and medical

innovation in Germany.”

Note to Editors: For pictures of the event, please contact

Bundespresseamt (Bundesbildstelle, Telephone: +49 (0)30 18 272-2332, bilderdienst@bpa.bund.de

and https://www.mdc-berlin.de/en/news/2011/index.html)

For more information about Pacific Biosciences, please visit www.pacificbiosciences.com.

About Pacific Biosciences

Pacific Biosciences’ mission is to transform the way humankind acquires,

processes and interprets data from living systems through the design,

development and commercialization of innovative tools for biological

research. The company has developed a novel approach to studying the

synthesis and regulation of DNA, RNA and proteins. Combining recent

advances in nanofabrication, biochemistry, molecular biology, surface

chemistry and optics, Pacific Biosciences has created a powerful

technology platform called single molecule, real-time, or SMRT™,

technology. SMRT technology enables real-time analysis of biomolecules

with single molecule resolution, which has the potential to transform

the understanding of biological systems by providing a window into these

systems that has not previously been open for scientific study.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking

statements may contain words such as “believe,” “may,” “estimate,”

“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of

these terms, or other similar expressions, and include the assumptions

that underlie such statements. Such statements include, but are not

limited to, statements regarding the Company’s SMRT technology. These

statements are subject to known and unknown risks and uncertainties that

could cause actual results to differ materially from those expressed or

implied by such statements, including but not limited to risks discussed

from time to time in documents Pacific Biosciences of California, Inc.

has filed with the Securities and Exchange Commission, including the

risks identified under the section captioned “Risk Factors” in its

recently filed Quarterly Report on Form 10-Q. All forward-looking

statements are based on estimates, projections and assumptions as of the

date hereof. Pacific Biosciences undertakes no obligation to update any

forward-looking statements.

Media:
For Pacific BiosciencesNicole

Litchfield, 415-793-6468
nicole@bioscribe.com
or
Investors:
Pacific

BiosciencesTrevin Rard, 650-521-8450
ir@pacificbiosciences.com

Source: Pacific Biosciences of California, Inc.

News Provided by Acquire Media